For patients using GLP-1 RAs for diabetes management, the AGA notes a lack of compelling evidence to support withholding doses, emphasizing that maintaining proper glycemic control is essential before undergoing sedation, anesthesia, and endoscopy procedures [22]. This evidence concerns the gene GLP1R and diabetes mellitus.